Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2026)

Recursion Pharmaceuticals has reported Change in Cash for 7 years, with the latest figure at -$88.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 5.46% year-over-year to -$88.7 million; the trailing twelve-month figure through Mar 2026 stood at $156.0 million (down 23.14% YoY), and the FY2025 full-year result was $150.9 million, down 25.15% from the prior year.
• Change in Cash for Q1 2026 stood at -$88.7 million, down from $86.8 million in the prior quarter.
• The five-year high for Change in Cash was $222.8 million in Q1 2022, with the low at -$95.3 million in Q1 2024.
• Historically, Change in Cash has averaged $21.8 million across 5 years, with a median of $780000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Cash sank 2615.0% — and 2024, when it soared 3863.8%.
• Recursion Pharmaceuticals' Change in Cash stood at $94.2 million in 2022, then tumbled by 95.52% to $4.2 million in 2023, then soared by 3863.8% to $167.2 million in 2024, then slumped by 48.1% to $86.8 million in 2025, then slumped by 202.26% to -$88.7 million in 2026.
• The last three Change in Cash figures came in at -$88.7 million (Q1 2026), $86.8 million (Q4 2025), and $133.3 million (Q3 2025), per Business Quant data.